Evidence map›Paper›PMID 38139797›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Radiosynthesis of Stable

Güllü Davarci, Carmen Wängler, Klaus Eberhardt, Christopher Geppert, Ralf Schirrmacher, Robert Freudenberg, Marc Pretze, Björn Wängler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. IntratumoralACS omega · 2026
    Article
  2. Synthesis and in vitro characterization of [EJNMMI radiopharmacy and chemistry · 2025
    Article
  3. Preclinical Evaluation of Stable Integrin αPharmaceuticals (Basel, Switzerland) · 2025
    Article
  4. Small science · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Güllü DavarciMolecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.
Carmen WänglerBiomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0003-1161-8669
Klaus EberhardtResearch Reactor TRIGA Mainz, Institute for Nuclear Chemistry, Johannes-Gutenberg-Universität Mainz, 55128 Mainz, Germany.
Christopher GeppertResearch Reactor TRIGA Mainz, Institute for Nuclear Chemistry, Johannes-Gutenberg-Universität Mainz, 55128 Mainz, Germany.
Ralf SchirrmacherDepartment of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0002-7098-3036
Robert FreudenbergDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
Marc PretzeMolecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0002-6432-5694
Björn WänglerMolecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0003-3877-5576
Heidelberg University · DEJohannes Gutenberg University Mainz · DEUniversity Hospital Carl Gustav Carus · DEUniversity of Alberta · CA

Funding

Federal Ministry of Education and Research 13GW0091B, 13GW0091E, 13GW0388A and 13GW0389B
6 · The paper itself

Abstract

This paper reports on the development of stable tumor-specific gold nanoparticles (AuNPs) activated by neutron irradiation as a therapeutic option for the treatment of cancer with high tumor angiogenesis. The AuNPs were designed with different mono- or dithiol-ligands and decorated with different amounts of Arg-Gly-Asp (RGD) peptides as a tumor-targeting vector for α

Indexed as

[198Au]AuNPsgold nanoparticlesradioactiveRGD peptidetumor angiogenesistumor therapy

Identifiers

PMID38139797
PMCPMC10747377
OpenAlexW4389192877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.